Japan Oncology Drugs Market Share and Trends
The Japan oncology drugs market size was accounted for $9,405 million in 2018, and is expected to reach $14,109 million by 2026, registering a CAGR of 5.2% from 2019 to 2026. Cancer is a chronic medical condition that involves an abnormal growth of cells. The abnormal growth of cells results in the formation of a tumor. Furthermore, these abnormal tumor cells have the tendency to spread to other local tissues through blood and lymphatic system. Different types of cancers such as colorectal, stomach cancer and others are predominant among the Japanese populace. Treatment of cancer depends upon the stages of the disease progression. Chemotherapy is majorly used in the earlier stages whereas other therapy options such as targeted therapy drugs, immunological therapy drugs are used in late stage.
Rise in incidence of cancer in Japan, surge in research related to new drug discovery for cancer treatment, and increase in healthcare expenditure are the major factors that fuel the growth of the Japan oncology drugs market. In addition, surge in awareness related to early diagnosis of cancer leading to rise in demand for oncology drugs for treatment boost the growth of the market in Japan. Furthermore, surge in geriatric population also contributes to the growth of the market as the elderly are more prone to certain cancers such as prostate cancer. In addition, rise in number of pipeline products is expected to provide lucrative opportunities during the forecast period. However, stringent approval process of oncology drugs in Japan hinders the growth of the market.
Japan Oncology Drugs Market Segmentation
The Japan oncology drugs market size is studied based on segment, drug class type, and indication. Based on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy, hormonal therapy. By indication, it is categorized into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer, ovarian cancer, cervical cancer, kidney cancer, and others.
Segment Review
Based on drug class type, the targeted therapy segment occupied the largest Japan oncology drugs market share in 2018 owing to lesser side effects of the drugs as compared to other treatment options. This is due to the ability of targeted therapies to kill only malignant cells thereby exhibiting better treatment outcomes. In addition, higher efficacy and higher survival rates associated with the use of targeted therapy drugs are other reasons that fuel the growth of the market. The immunotherapy segment is expected to show fastest growth during the forecast period owing to surge in incidence of cancer worldwide and high unmet medical needs in some countries. Moreover, immunotherapy drugs are widely accepted as an ideal treatment option as these drugs are potentially harmless to the other living cells of the body, which makes them less toxic as compared to other modes of cancer therapies. Furthermore, continuous efforts in R&D to design and develop new immunotherapeutic for the treatment of various cancer types serves as a key factor for the Japan oncology drugs market growth.
According to indication, the prostate cancer segment occupied the largest Japan oncology drugs market share in 2018. This is due to presence of huge geriatric population. The lung cancer segment is expected to experience fastest growth during the forecast period. This is due to technological developments in the field of cancer diagnostics and rise in the awareness related to the early diagnosis of cancer.
The Japan oncology drugs market is highly competitive and the prominent players in the market have adopted various strategies for garnering maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Otsuka Holdings Co Ltd, Johnson and Johnson, Daiichi Sankyo Co Ltd, AstraZeneca plc, AbbVie Inc., Celgene Corporation, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Astellas Pharma Inc., and Takeda Pharmaceutical Company Ltd
Key Benefits for Japan Oncology Drugs Market :
- This report entails a detailed quantitative analysis along with the current Japan oncology drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
- The Japan oncology drugs market forecast is studied from 2019 to 2026.
- The market size and estimations are based on a comprehensive analysis of key developments in the Japan oncology drugs industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Japan Oncology Drugs Market, by Drug Class Type Report Highlights
| Aspects | Details |
 By Drug Class Type |
|
 By Indication |
|
 Key Market Players | Bristol-Myers Squibb Company, Otsuka Holdings Co., Ltd., ABBVIE INC., Daiichi Sankyo Company, Limited, Celgene Corporation, Hoffmann-La Roche AG, Takeda Pharmaceutical Company Ltd., Astellas Pharma Inc., Johnson & Johnson (Janssen Pharmaceuticals, Inc.), AstraZeneca plc |
Analyst Review
Cancer is a large group of diseases that represent an abnormal growth of cells and tend to proliferate in an uncontrolled manner. Cancer is mostly named after the organ in which it initiates. For instance, lung cancer, breast cancer, colorectal, prostate cancer, and others. There are different treatments available for cancer such as chemotherapy, immunotherapy, and others. The management of cancer by the use of drugs is different in every patient as the treatment depends on the tumor progression.
The key factor responsible for the growth of the Japan oncology drugs market is increase in prevalence of cancer. Furthermore, the market growth is also propelled by surge in geriatric population, increase in collaboration between pharmaceutical companies for development of novel cancer drugs, and rise in awareness associated with early detection of cancer among populace. In addition, surge in geriatric population also contributes to the growth of the market as the elderly are more prone to certain cancers such as prostate cancer.
Moreover, rise in number of pipeline products is expected to provide lucrative opportunities during the forecast period. However, stringent approval process of oncology drugs in Japan hinders the growth of the market.
Loading Table Of Content...
